Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Nephrology Dialysis Transplantation

Volumn 31, Issue 3, 2016, Pages 337-348

  Gansevoort, Ron T ^a   Arici, Mustafa ^b   Benzing, Thomas ^c   Birn, Henrik ^d,e   Capasso, Giovambattista ^f   Covic, Adrian ^g   Devuyst, Olivier ^h,i   Drechsler, Christiane ^j   Eckardt, Kai Uwe ^k   Emma, Francesco ^l   Knebelmann, Bertrand ^m   Le Meur, Yannick ⁿ   Massy, Ziad A ^o,p,q   Ong, Albert C M ^r   Ortiz, Alberto ^s   Schaefer, Franz ^t   Torra, Roser ^u,v   Vanholder, Raymond ^w   Więcek, Andrzej ^x   Zoccali, Carmine ^y   Van Biesen, Wim ^w   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HACETTEPE UNIVERSITY   (Turkey)

^c UNIVERSITY OF COLOGNE   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ UCL   (Belgium)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^m HÔPITAL NECKER ENFANTS MALADES   (France)

ⁿ UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^o HÔPITAL AMBROISE PARÉ   (France)

^p CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^q UNIVERSITÉ PARIS SACLAY   (France)

^r UNIVERSITY OF SHEFFIELD   (United Kingdom)

^s Instituto de Investigación Sanitaria Fundación Jiménez Díaz   (Spain)

^t UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^u UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^v REDINREN   (Spain)

^w GHENT UNIVERSITY HOSPITAL   (Belgium)

^x MEDICAL UNIVERSITY OF SILESIA   (Poland)

^y BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

more..

Author keywords

ADPKD; tolvaptan; vasopressin V2 receptor antagonist

Indexed keywords

CREATININE; PLACEBO; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ALGORITHM; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DISEASE SURVEILLANCE; DRUG CONTRAINDICATION; DRUG COST; EUROPEAN; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY POLYCYSTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT IDENTIFICATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL SYSTEM PARAMETERS; REVIEW; RISK ASSESSMENT; TOTAL KIDNEY VOLUME; ADULT; DISEASE COURSE; EUROPE; GENETICS; HYPONATREMIA; MEDICAL SOCIETY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

ADULT; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; DISEASE PROGRESSION; EUROPE; HUMANS; HYPONATREMIA; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SOCIETIES, MEDICAL;

EID: 84960078548     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv456     Document Type: Review

References (52)

1. Steinman TI. Polycystic kidney disease: a 2011 update. Curr Opin Nephrol Hypertens 2012; 21: 189-194
2. Devuyst O, Knoers NV, Remuzzi G, et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 2014; 383: 1844-1859
3. Spithoven EM, Kramer A, Meijer E, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 2014; 29 (Suppl 4): iv15-iv25
4. Spithoven EM, Kramer A, Meijer E, et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int 2014; 86: 1244-1252
5. Cornec-Le Gall E, Audrézet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 2013; 24: 1006-1013
6. Grantham JJ. Autosomal dominant polycystic kidney disease.NEngl J Med 2008; 359: 1477-1485
7. Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 2015; 385: 1993-2002
8. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease.Nat RevNephrol 2011; 7: 556-566
9. Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2015; 88: 17-27
10. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418
11. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
12. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884
13. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
15. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 2014; 311: 2518-2531
16. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64: 821-835
17. European Medicines Agency. Guideline on the Clinical Investigation of Medicinal Products to Prevent Development/Slow Progression of Chronic Renal Insufficiency. https://www.google.nl/search?q=EMA%2FCHMP%2F355988%2F2014& ie=utf-8& oe=utf-8& aq=t& rls=org.mozilla: nl: official& client=firefox-a& channel=fflb& gfe-rd=cr& ei=gXF4VqT2JYO-Qan84OADQ (10 November 2015, date last accessed
18. European Medicines Agency. Public Assessment Report Jinarc. http://www. ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment- report/human/002788/WC500187923.pdf (10 November 2015, date last accessed
19. Reference to FDA Complete Response Letter 2013. http://www.businesswire. com/news/home/20130829006215/en/Otsuka-Receives-Complete-Response-Letter-U.S.-Food (10 November 2015, date last accessed
20. Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830-838
21. The REPRISE Study. Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease. https://clinicaltrials.gov/ct2/show/NCT02160145 (10 November 2015, date last accessed
22. National Institute for Health and Care Excellence. Final Appraisal Determination: Tolvaptan for Treating Autosomal Dominant Polycystic Kidney Disease. http://www.nice.org.uk/guidance/TA358/documents/kidneydisease-autosomal-dominant-polycystic-tolvaptan-id652-final-appraisaldetermination-document2 (10 November 2015, date last accessed
23. Torres VE, Higashihara E, Devuyst O, et al. Effect of tolvaptan in ADPKD by CKD stage: results from the TEMPO 3: 4 trial. Clin J Am Soc Nephrol 2015; accepted for publication
24. Schrier RW, Brosnahan G, Cadnapaphornchai MA, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol 2014; 25: 2399-2418
25. Woon C, Bielinski-Bradbury A, O'Reilly K, et al. A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol 2015; 16: 140
26. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7: 479-486
27. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1: 148-157
28. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130
29. Higashihara E, Horie S, Muto S, et al. Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 2012; 16: 622-628
30. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015; 26: 160-172
31. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29
32. Ruggenenti P, Gaspari F, Cannata A, et al. Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. PLoS One 2012; 7: e32533
33. Orskov B, Borresen ML, Feldt-Rasmussen B, et al. Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease.Am J Nephrol 2010; 31: 53-57
34. Spithoven EM, Meijer E, Boertien WE, et al. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for crosssectional and longitudinal performance of kidney function estimating equations. Am J Kidney Dis 2013; 62: 531-540
35. Kidney Disease: Improving Global Outcomes (KDIGO) CKDWork Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150
36. Bae KT, Grantham JJ. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010; 6: 96-106
37. Kistler AD, Poster D, Krauer F, et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75: 235-241
38. Spithoven EM, van Gastel MD, Messchendorp AL, et al. Estimation of total kidney volume in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2015; 66: 792-801
39. Clinical Guidelines for Polycystic Kidney Disease 2014 Advisory Committee. Evidence-Based Clinical Practice Guidelines for Polycystic Kidney Disease 2014. Japan. http://www.jsn.or.jp/BCD1572E-0531-492B-BBDD-803B7BF77CE2/FinalDownload/DownloadId-BA08C144CD972059AB5B1F6CCB4D1BE5/BCD1572E-0531-492B-BBDD-803B7BF77CE2/guideline/pdf/PKD-eng.pdf (10 November 2015, date last accessed
40. Mayo ADPKD Class Calculator. http://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754 (10November 2015, date last accessed
41. Bhutani H, Smith V, Rahbari-Oskoui F, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int 2015; 88: 146-151
42. Cornec-Le Gall E, Audrézet MP, Rousseau A, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2015; doi: 10.1681/ASN.2015010016
43. Persu A, Duyme M, Pirson Y, et al. Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 2004; 66: 2132-2136
44. Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009; 20: 1833-1838
45. European Medicines Agency. Summary of Medicinal Product Characteristics Jinarc. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002788/WC500187921.pdf (10 November 2015, date last accessed
46. Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical pattern of tolvaptanassociated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database.Drug Saf 2015; 38: 1103-1113
47. FDA. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation, 2009. http://www.fda.gov/downloads/Drugs/Guidance/UCM174090.pdf (10 November 2015, date last accessed
48. FDA Briefing Document NDA 204441. Delaying Progression of Renal Complications of ADPKD by Tolvaptan Inhibition of Arginine Vasopressin, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM363345.pdf (10 November 2015, date last accessed
49. Boertien WE, Meijer E, de Jong PE, et al. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Kidney Int 2013; 84: 1278-1286
50. Hems DA, Whitton PD. Stimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver. Biochem J 1973; 136: 705-709
51. Irazabal MV, Torres VE, HoganMCet al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011; 80: 295-301
52. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO guideline glomerulonephritis. Kidney Int Suppl 2012; 2: 209-217